Fresenius Kabi to Announce Winner of EUR 100,000* Research Grant to Support Parenteral Nutrition Research in Latin America at the FELANPE Congress in Mexico

Bad Homburg (ots) - Global healthcare company Fresenius Kabi will
announce the winner of the first EUR 100,000* Parenteral Nutrition
Research Grant Latin America at the FELANPE congress in Guadalajara,
Mexico, from September 22-25.

The announcement will be made during Fresenius Kabi's satellite
symposium, in Salón 7, on September 24, from 10.45am - 12.45pm (CDT).

The EUR 100,000* winner will be a healthcare professional with an
original research project directly related to the therapeutic area of
parenteral nutrition. The funding is for a research project lasting
two years, starting in October 2018. Results of the project are
expected to be presented at the FELANPE congress in 2020.

Fifty-one applications from nine countries across Latin America
were received for the first ever Parenteral Nutrition Research Grant
Latin America. The majority of applicants came from Brazil and
Mexico. The winner has been chosen by an independent Research Grant
Committee, consisting of renowned key opinion leaders in the field of
clinical nutrition in Latin America and was chaired by Prof. Isabel
Correia, the former FELANPE president.

With this research grant, Fresenius Kabi aims to encourage and
support clinical research, advancing the use of parenteral nutrition
across Latin America, within the scope of its initiative 'United for
clinical nutrition'. Once developed, these insights contribute to
improving patient outcomes across the region.

*Euro amount or equivalent in local currency

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in
lifesaving medicines and technologies for infusion, transfusion and
clinical nutrition. The company's products and services are used to
help care for critically and chronically ill patients. Fresenius
Kabi's product portfolio comprises a comprehensive range of I.V.
generic drugs, infusion therapies and clinical nutrition products as
well as the medical devices for administering these products. Within
transfusion technologies, Fresenius Kabi offers products for
collection and processing of blood components and for therapeutic
treatment of patient blood by apheresis systems. In the field of
biosimilars, Fresenius Kabi develops products with a focus on
oncology and autoimmune diseases.

With its corporate philosophy of "caring for life", the company is
committed to putting essential medicines and technologies in the
hands of people who help patients and finding the best answers to the
challenges they face.

For more information, please visit www.fresenius-kabi.com.

Media Relations Contact:
Isabel Cochrane
+49 (0)69/401254353
Isabel.Cochrane@edelman.com

Original-Content von: Fresenius Kabi, übermittelt durch news aktuell